Akebia Therapeutics
AKBA
89 hedge funds and large institutions have $191M invested in Akebia Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 14 closing their positions.
190% more call options, than puts
Call options by funds: $933K | Put options by funds: $322K
0.89% more ownership
Funds ownership: 52.74% → 53.63% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
5% less funds holding
Funds holding: 94 → 89 (-5)
9% less capital invested
Capital invested by funds: $210M → $191M (-$18.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.2M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$12.4M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.9M |
| 4 |
Renaissance Technologies
New York
|
+$1.73M |
| 5 |
Millennium Management
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$7.28M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.21M |
| 3 |
PA
Perceptive Advisors
New York
|
-$4.76M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$3.66M |
| 5 |
CFIC
City Financial Investment Company
London,
United Kingdom
|
-$1.28M |
AKBA Hedge Fund Activity: Q1 2017 in Review
89 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2017, worth a combined $191M — down 9% from $210M a quarter earlier.
Fund positioning in AKBA was balanced in Q1 2017: 14 funds opened new positions, 14 closed out, 28 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $26.2M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $7.28M sold.
- 89 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2017, down from 94 in Q4 2016.
- Funds reported $191M of Akebia Therapeutics stock for Q1 2017, down 9% quarter-over-quarter.
- 14 funds opened new Akebia Therapeutics positions in Q1 2017 and 14 closed out, a net change of 0 holders.
- The largest Akebia Therapeutics buyer in Q1 2017 was BlackRock, an estimated $26.2M added.
- The largest Akebia Therapeutics seller in Q1 2017 was Acuta Capital Partners, an estimated $7.28M sold.
Based on aggregated 13F filings for Q1 2017.